RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/02/2025 16:30 PDT] RenovoRx, Inc. (NASDAQ:RNXT), Up By 100% ($0.9) From $0.9 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/26/2025 07:22 PDT] RNXT Expected to Trade Up After Bullish Patterns Develop
• [08/15/2025 07:17 PDT] RNXT Expected to Trade Up After Bullish Patterns Develop
• [07/07/2025 09:45 PDT] RNXT Expected to Trade Up After Bullish Patterns Develop